A Phase 4 interventional study of Cyclosporine and Mycophenolate mofetil in Renal Function and Chronic Allograft Vasculopathy, sponsored by Novartis Pharmaceuticals. Completed at 6 sites in 3 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2015-06-10.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A controlled, randomized, open-label, multicenter study evaluating if early initiation of everolimus and early elimination of cyclosporine in de novo heart transplant recipients can improve long-term renal function and slow down the progression of chronic allograft vasculopathy
This was a prospective, multi-center, randomized, controlled, parallel group, open label study in de novo heart transplant recipients. Patients eligibility for randomization was assessed 5 days after heart transplant.. Patients fulfilling the inclusion and exclusion criteria were randomized to one of two treatment groups: either conventional treatment with Cyclosporine A (CsA), Mycophenolate mofetil (MMF), and corticosteroids (Group A), or low-dose CsA and everolimus, reduced dose MMF, and corticosteroids (Group B). After 7 to 11 weeks, CsA was discontinued in Group B, while the standard triple-drug immunosuppressive regimen was maintained in Group A.
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
De novo heart transplant recipients who had received induction therapy with antithomocyte globulin (ATG) were eligible for inclusion.
Recipients of multi-organ transplants or a previous transplant were excluded, as were those with a donor aged > 70 years, cold ischemia time >6 hours, patients with severe systemic infection, recipients of ABO incompatible transplants, patients with severe hypercholesterolemia (>350mg/dL) or hypertriglyceridemia (>750 mg/dL), patients with past (\<5 years). In order to continue in the study after week 7-11 (period 1), patients had to complete first 7-11 weeks on randomized and none of the following criteria should be present: Ongoing rejection treatment or experience of one grade 3R rejection or two or more grade 2R rejections during first 7-11 weeks.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants started immunosuppressive regimen consisting of low dose CsA, everolimus, MMF and CS. After week 11, the participants regimen consisted of everolimus, MMF and CS.
Drug: Cyclosporine · Drug: Mycophenolate mofetil · Drug: Corticosteroids · Drug: Everolimus · Drug: Anti Thymocyte Globulin
Participants received an immunosuppressive regimen consisting of CsA, MMF and CS throughout the study.
Drug: Cyclosporine · Drug: Mycophenolate mofetil · Drug: Corticosteroids · Drug: Anti Thymocyte Globulin
Cyclosporine (CsA) control group target blood level: 150-350 ng/mL (month 1-3); 100-250 ng/mL (month 4-6); 60-200 ng/mL (month 7-12); everolimus group target blood level: 75-175 ng/mL (month 1-3)
Mycophenolate mofetil (MMF) target dose for control group: 2000-3000 mg/day everolimus group target dose: 1500-2000 mg/day and 75-175 ng/mL after week 11
Corticosteroids (CS) initiated at 0.2-0.5 mg/kg/day. Tapered to no less than 0.1 mg/kg at Month 3 for control and everolimus groups.
Everolimus 0.75 mg twice a day as starting dose up to a target blood level: 3-6 ng/mL (7-11 weeks) and 6-10 ng/mL for remaining of study
Induction therapy, Anti Thymocyte Globulin (ATG): 1-2 mg/kg/day during 3-5 days for control and everolimus groups after transplant surgery and prior to randomization.
Measured Glomerular Filtration Rate (mGFR), 12 Months After Heart Transplantation
Measured Glomerular Filtration Rate (mGFR) describes the flow rate of filtered fluid through the kidney. GFR is equal to the clearance rate when any solute is freely filtered and is neither reabsorbed nor secreted by the kidneys. The rate therefore measured is the quantity of the substance in the urine that originated from a calculable volume of blood. Participants' urine was used for this assessment at week 52 after heart transplant.
Time frame: Week 52
Progression of Chronic Allograft Vasculopathy (CAV) Based on Maximal Intimal Thickness (MIT) From Baseline to Week 52
The progression of chronic allograft vasculopathy (CAV) was assessed by intravascular ultrasound (IVUS) examinations and measured Maximal Intimal Thickness (MIT)(in mm). A major coronary epicardial artery (preferentially the left-anterior descending coronary artery) was imaged, and the MIT parameters were recorded at baseline and at week 52.
Time frame: Baseline and week 52
Progression of Chronic Allograft Vasculopathy (CAV) Based on Incidence of Chronic Allograft Vasculopathy (CAV) From Baseline to Week 52
the progression of chronic allograft vasculopathy (CAV) assessed by intravascular ultrasound (IVUS) examinations, measured the incidence of CAV (in percent of patients) at baseline and at week 52. Incidence of CAV represents percent of patients having a MIT (maximal intima thickness) \> 0.5 mm.
Time frame: Baseline and week 52
Change in Calculated Glomerular Filtration Rate From Pre-transplantation to Week 52
Change in calculated glomerular filtration rate from pre-transplantation to week 52 was calculated according to the Modification of Diet in Renal Disease (MDRD) method. Measurements were taken prior to transplant (day 1), between weeks 7 to 11 and end week 52.
Time frame: Day 1, weeks 7 to 11(baseline) and of week 52
Calculated Glomerular Filtration Rate From Pre-Transplantation to Week 52
Calculated Glomerular Filtration Rate from pre-transplantation to week 52 was calculated according to the Modification of Diet in Renal Disease (MDRD) method. Measurements were taken prior to transplant (day 1), between weeks 7 to 11 and end of week 52.
Time frame: Day 1, weeks 7 to 11 and of week 52
Number of Rejections Leading to Hemodynamic Compromise
Number of all rejections were recorded through the duration of the study with the intent to identify rejections leading to hemodynamic compromise.
Time frame: 52 weeks
Occurrence of Treatment Failures up to 12 Months After Transplant
Treatment failure was defined as the number of participants who died or lost their graft at any timepoint througout the duration of the study.
Time frame: 52 weeks
Average Level of Protenuria at Week 52
Proteinuria is measured as the ratio of albumin/creatinine mg/mmol. Measurements were taken from participants urine samples.
Time frame: 52 weeks
Lipid Profile at 12 Months
Total Cholesterol, LDL-Chol, HDL-Chol and TG at week 52. Measurements were taken via participants blood samples.
Time frame: 52 weeks
Change in Quality of Life Assessed by SF-36 (Minnesota Living With Heart Failure Questionnaire ([MLHF)]) From Pre-transplant to Week 52 of Treatment
Change in Quality of Life was assessed via the SF-36 (Minnesota Living with Heart Failure questionnaire (\[MLHF)\]) before transplant surgery and at week 52 of treatment. The SF-36 is a validated, self-administered questionnaire. The questionnaire, which includes 36 questions measures 8 dimensions of health: physical function, role-physical, bodily pain, general health, vitality, social function, role-emotional, and mental health. Scores can be summarized in 2 summary components assessing physical and mental health. Items in each dimension are coded, aggregated, summed, and transformed into a scale ranging from 0 (worse health) to 100 (best health).
Time frame: Pre transplant and 52 weeks
Change in Quality of Life - Euro Quality of Life 5D (EQ-5D)
Change in Quality of Life was assessed via the EQ-5D questionnaire which consists of: EQ-5D-5L descriptive system and EQ Visual Analogue scale (EQ VAS). The EQ-5D-5L comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression). Each dimension has 5 levels (no problems, slight problems, moderate problems, severe problems, and extreme problems). The patient indicates his/her health state by checking the most appropriate statement. This decision results in a 1-digit number expressing the level selected for that dimension. The digits for 5 dimensions are combined in a 5-digit number describing the respondent's health state. The possible score is 1 to 5 where a lower number indicates improvement. The EQ VAS records the patient's self-rated health on a 20 cm vertical, visual analogue scale with endpoints labelled 'the best health you can imagine' and 'the worst health you can imagine'. The score is 0 to 100 where a higher score represents improvement.
Time frame: Pre transplant and 52 weeks
115 patients (56 in the everolimus group, 59 in the control group) were randomized and received study treatment.
| Milestone | Everolimus | Control |
|---|---|---|
| Started | 56 | 59 |
| Completed | 49 | 56 |
| Not completed | 7 | 3 |
| Withdrew: Adverse event | 2 | 0 |
| Withdrew: Ongoing rejection | 1 | 0 |
| Withdrew: 2 2r rejections | 1 | 0 |
| Withdrew: Death | 2 | 3 |
| Withdrew: Missing mgfr value + ae | 1 | 0 |
Measured Glomerular Filtration Rate (mGFR) describes the flow rate of filtered fluid through the kidney. GFR is equal to the clearance rate when any solute is freely filtered and is neither reabsorbed nor secreted by the kidneys. The rate therefore measured is the quantity of the substance in the urine that originated from a calculable volume of blood. Participants' urine was used for this assessment at week 52 after heart transplant.
| mGFR ml/min | Everolimus | Control |
|---|---|---|
| Measured Glomerular Filtration Rate (mGFR), 12 Months After Heart Transplantation | 79.8 ± 17.7 | 61.5 ± 19.6 |
The progression of chronic allograft vasculopathy (CAV) was assessed by intravascular ultrasound (IVUS) examinations and measured Maximal Intimal Thickness (MIT)(in mm). A major coronary epicardial artery (preferentially the left-anterior descending coronary artery) was imaged, and the MIT parameters were recorded at baseline and at week 52.
| mm | Everolimus | Control |
|---|---|---|
| Baseline (Week 7) | 0.52 ± 0.22 | 0.56 ± 0.24 |
| Week 52 | 0.55 ± 0.24 | 0.65 ± 0.25 |
the progression of chronic allograft vasculopathy (CAV) assessed by intravascular ultrasound (IVUS) examinations, measured the incidence of CAV (in percent of patients) at baseline and at week 52. Incidence of CAV represents percent of patients having a MIT (maximal intima thickness) \> 0.5 mm.
| Percentage of patients | Everolimus | Control |
|---|---|---|
| No CAV at baseline (week 7) | 43.5 | 47.9 |
| CAV at baseline (week 7) | 56.5 | 52.1 |
| No CAV at week 52 | 50 | 35.4 |
| CAV at week 52 | 50 | 64.6 |
Change in calculated glomerular filtration rate from pre-transplantation to week 52 was calculated according to the Modification of Diet in Renal Disease (MDRD) method. Measurements were taken prior to transplant (day 1), between weeks 7 to 11 and end week 52.
| mGFR mL/min | Everolimus | Control |
|---|---|---|
| Day 1 (n= 43, 47) | -13.0 ± 28.2 | -12.6 ± 32.6 |
| Weeks 7 to 11 (n= 46, 49) | 7.4 ± 32.6 | -6.8 ± 26.2 |
| Week 52 (n= 42, 53) | 27.8 ± 49.9 | -8.0 ± 28.3 |
Calculated Glomerular Filtration Rate from pre-transplantation to week 52 was calculated according to the Modification of Diet in Renal Disease (MDRD) method. Measurements were taken prior to transplant (day 1), between weeks 7 to 11 and end of week 52.
| mGFR mL/min | Everolimus | Control |
|---|---|---|
| Day 1 (n= 46, 48) | 65.4 ± 33.8 | 66.1 ± 28.7 |
| Weeks 7 to 11 (n=50, 51) | 84.9 ± 40.5 | 69.6 ± 19.9 |
| Week 52 (n= 45, 55) | 104.5 ± 54.0 | 69.3 ± 20.4 |
Number of all rejections were recorded through the duration of the study with the intent to identify rejections leading to hemodynamic compromise.
| rejections | Everolimus | Control |
|---|---|---|
| Total rejection | 185 | 128 |
| Treated rejection | 43 | 17 |
| Rejections with hemodynamic compromise | 0 | 0 |
Treatment failure was defined as the number of participants who died or lost their graft at any timepoint througout the duration of the study.
| participants | Everolimus | Control |
|---|---|---|
| Treatment failure (death) | 2 | 3 |
| Graff loss | 0 | 0 |
| Total treatment failures (graft loss + death | 2 | 3 |
Proteinuria is measured as the ratio of albumin/creatinine mg/mmol. Measurements were taken from participants urine samples.
| mg/mmol | Everolimus | Control |
|---|---|---|
| Average Level of Protenuria at Week 52 | 7.2 ± 12.8 | 1.2 ± 1.4 |
Total Cholesterol, LDL-Chol, HDL-Chol and TG at week 52. Measurements were taken via participants blood samples.
| mmol/L | Everolimus | Control |
|---|---|---|
| Total cholesterol | 5.3 ± 1.1 | 5.1 ± 1.0 |
| LDL-C | 2.9 ± 1.0 | 2.8 ± 0.8 |
| HDL-C | 1.6 ± 0.5 | 1.6 ± 0.5 |
Change in Quality of Life was assessed via the SF-36 (Minnesota Living with Heart Failure questionnaire (\[MLHF)\]) before transplant surgery and at week 52 of treatment. The SF-36 is a validated, self-administered questionnaire. The questionnaire, which includes 36 questions measures 8 dimensions of health: physical function, role-physical, bodily pain, general health, vitality, social function, role-emotional, and mental health. Scores can be summarized in 2 summary components assessing physical and mental health. Items in each dimension are coded, aggregated, summed, and transformed into a scale ranging from 0 (worse health) to 100 (best health).
| Units on a scale | Everolimus | Control |
|---|---|---|
| Physical Health pre- transplant | 30.8 ± 11.1 | 32.9 ± 8.0 |
| Physical Health at week 52 | 48.8 ± 9.6 | 48.8 ± 8.3 |
| Mental Health pre- transplant | 46.2 ± 11.8 | 38.7 ± 12.4 |
| Mental Health at week 52 | 51.5 ± 12.2 | 53.9 ± 7.2 |
Change in Quality of Life was assessed via the EQ-5D questionnaire which consists of: EQ-5D-5L descriptive system and EQ Visual Analogue scale (EQ VAS). The EQ-5D-5L comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression). Each dimension has 5 levels (no problems, slight problems, moderate problems, severe problems, and extreme problems). The patient indicates his/her health state by checking the most appropriate statement. This decision results in a 1-digit number expressing the level selected for that dimension. The digits for 5 dimensions are combined in a 5-digit number describing the respondent's health state. The possible score is 1 to 5 where a lower number indicates improvement. The EQ VAS records the patient's self-rated health on a 20 cm vertical, visual analogue scale with endpoints labelled 'the best health you can imagine' and 'the worst health you can imagine'. The score is 0 to 100 where a higher score represents improvement.
| Units on a scale | Everolimus | Control |
|---|---|---|
| EQ-5D-5L pre- transplant (n=45,49) | 0.5750 ± 0.3387 | 0.5069 ± 0.3209 |
| EQ-5D-5L at week 52 (n=41,44) | 0.8329 ± 0.2638 | 0.8367 ± 0.2234 |
| EQ VAS pre- transplant (n=41,48) | 46.0 ± 24.3 | 38.9 ± 20.8 |
| EQ VAS at week 52 (n=41,42) | 80.0 ± 15.0 | 79.4 ± 11.5 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Controls | — | 27/59 (45.8%) | 53/59 (89.8%) |
| Everolimus | — | 27/56 (48.2%) | 47/56 (83.9%) |
| Event | Controls | Everolimus |
|---|---|---|
| PneumoniaInfections and infestations | 1/59 | 5/56 |
| Cardiac disorderCardiac disorders | 1/59 | 3/56 |
| DiarrhoeaGastrointestinal disorders | 3/59 | 0/56 |
| PyrexiaGeneral disorders | 3/59 | 0/56 |
| Cytomegalovirus infectionInfections and infestations | 3/59 | 0/56 |
| InfectionInfections and infestations | 3/59 | 1/56 |
| DepressionPsychiatric disorders | 0/59 | 2/56 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 1/59 | 2/56 |
| Multi-organ failureGeneral disorders | 2/59 | 1/56 |
| EpilepsyNervous system disorders | 2/59 | 0/56 |
| Event | Controls | Everolimus |
|---|---|---|
| HypertensionVascular disorders | 20/59 | 10/56 |
| Cytomegalovirus infectionInfections and infestations | 15/59 | 3/56 |
| LeukopeniaBlood and lymphatic system disorders | 13/59 | 11/56 |
| Oedema peripheralGeneral disorders | 10/59 | 12/56 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 7/59 | 11/56 |
| DiarrhoeaGastrointestinal disorders | 2/59 | 10/56 |
| InfectionInfections and infestations | 9/59 | 10/56 |
| NasopharyngitisInfections and infestations | 7/59 | 9/56 |
| ArrhythmiaCardiac disorders | 9/59 | 6/56 |
| AnaemiaBlood and lymphatic system disorders | 5/59 | 8/56 |
| Age, Continuous(years) | Everolimus | Control | Total |
|---|---|---|---|
| Mean | 51.02 ± 12.93 | 51.47 ± 12.36 | 51.25 ± 12.59 |
| Sex: Female, Male(Participants) | Everolimus | Control | Total |
|---|---|---|---|
| Female | 17 | 14 | 31 |
| Male | 39 | 45 | 84 |
The record gives a start of Nov 2009, a primary completion of Dec 2012 and a completion of Dec 2012. It does not say whether these dates are actual or estimated.
Results were first posted in May 2014, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Everolimus